Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells

Annals of the Romanian Society for Cell Biology

Volumn 17, Issue 1, 2012, Pages 194-200

  Gherman, Claudia ^a,b   Pileczki, Valentina ^c   Petric, Roxana Cojocneanu ^c   Rapuntean, S ^b   Gherman, Sonia ^b   Neagoe, Ioana Berindan ^a,d  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

^c BABE BOLYAI UNIVERSITY   (Romania)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Colorectal cancer; NF B; Oxaliplatin; P53; PDGF

Indexed keywords

EID: 84864343011     PISSN: 15836258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adamsa, R.A.; Meadeb, A.M.; Seymourc, M.T.; Wilsond, R.H.; Madia, A.; Fisherb, D., et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 12(7), 642-653, 2011
2. Alcindor, T. and Beauger, N. Oxaliplatin: a review in the era of molecularly targeted therapy. Current Oncology. 18(1), 18-25, 2011
3. Azmi, A.S.; Banerjee, S.; Ali, S.; Wang, Z.; Bao, B.; Beck, F.W.B.; Maitah, M., et al. Network modeling of MDM2 inhibitoroxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2, 378-392, 2011
4. Baker, S J.; Preisinger, A.C.; Jessup, J.M.; Paraskeva, C.; Markowitz, S.; Willson, J.K.; Hamilton, S. and Vogelstein, B. P53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50,7717, 1990
5. Banerjee, S.; Kaseb, A.O.; Wang, Z.; Kong, D.; Mohammad, M.; Padhye, S.; Sarkar, F.H. and Mohammad, R.M. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 69, (13), 2009
6. Chen, G.X.; Zheng, L.H.; Liu, S.Y. and He, X.H. rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J. Gastroenterol. 17(38), 4289-4297, 2011
7. Chirilǎ, D. N., Pop, T. R., Turdeanu, N. A., Tubular carcinoid tumor of the appendix - a clinical case. HVM Bioflux 3(1), 1-4, 2011.
8. de Bruijn, M.T.; Raats, D.A.E.; Hoogwater, F.J.H.; van Houdt, W.J.; Cameron, K.; Medema, J.P; Borel Rinkes, I.H.M. and Kranenburg, O. Oncogenic KRAS sensitizes colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. British Journal of Cancer. 102, 1254-1264, 2010
9. du Plessis-Stomana, D.; du Preezb, J.G.H. and van de Venter, M. Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFKB in cancer cell lines. Afr. J. Tradit. Complement Altern Med. 8(2),177-184, 2011
10. Guan, Y.S.; Liu, Y.; Sun, L.; Li, X.; He, Q. Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization. World J. Gastroenterol. 11, 3803-3805, 2005
11. Hollstein, M.; Sidransky, D.; Vogelstein, B. and Harris, C.C. p53 mutations in human cancers. Science 253, 49-53, 1991
12. Hussain, S.P.; Amstad, P.; Raja, K.; Ambs, S.; Nagashima, M.; Bennett, W.P. et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60:3333, 2000
13. Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321, 1801-1806, 2008
14. Kin, Y.S.; Lee, H.J.; Jang, C.; Kim, H.S. and Cho, Y.J. Knockdown of RCAN 1.4 increases susceptibility to FAS-mediated and DNA damage-induced apoptosis by upregulation of p53 expression. Korean J. Physiol. Pharmacol. 13, 483-9, 2009
15. Klein, W.M.; Hruban, R.H.; Klein-Szanto, A.J. and Wilentz, R.E. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15, 441-447, 2009
16. Knijn, N.; Tol, J. and Punt, C.J. Current issues in the targeted therapy of advanced colorectal cancer. Discov Med. 9(47):328-36, 2010
17. Midgley, R.S.; Yanagisawa, Y. and Kerr, D.J. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 6, 108-120, 2009
18. Nemoto, S.; Nakamura, M.; Osawa, Y.; Kono, S.; Itoh, Y.; Okano, Y., et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. The Journal of Biological Chemistry. 284, (16), 10422-10432, 2009
19. Peng, Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016-1027, 2005
20. Royds, J.A.; Dower, S.K.; Qwarnstrom, E.E. and Lewis, C.E. Response of tumour cells to hypoxia: role of p53 and NFkB. Clin. Pathol.: Mol. Pathol. 51,55-61, 1998
21. Stewart, B.W.; Kleihues, P.; World Cancer Report. IARC non-serial publication. Lyon: IARC, 2003
22. Suh, S.H.; Kwon, H.C.; Jo, J.H.; Cho, Y.R.; Seo, B.G.; Lee, M.D.; Kim, S.H. et al.; Oxaliplatin with beweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. Cancer Res. Treat. 37, 279-83, 2005
23. Temmink, O.H.; Prins, H.J.; van Gelderop, E. and Peters G.J. The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br. J. Cancer. 96(1), 61-66, 2007
24. Weekes, J.; Lam, A.K.; Sebesan, S. and Ho, Y.H. Irinotecan therapy and molecular targets in colorectal cancer: A systemic review. World J 15(29), 3597-3602, 2009
25. Wu, H. and Lozano, G. NFkB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem. 269, 20067-74, 1994
26. Yang, C.; Liu, H.Z. and Fu, Z.X. PEGliposomal oxaliplatine induced apoptosis in human colorectal cancer cells via Fas/FasL and Caspase-8. Cell Biology International. 36(3),289-96, 2011